Kyverna Therapeutics, Inc. (KYTX) Revenue History
Annual and quarterly revenue from 2021 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KYTX Revenue Growth
KYTX Revenue Analysis (2021–2024)
As of May 8, 2026, Kyverna Therapeutics, Inc. (KYTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, KYTX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $7.0 million in 2022.
When compared to Healthcare sector peers including AUTL (+406.7% YoY), BEAM (+108.0% YoY), and LEGN (+64.2% YoY). Compare KYTX vs AUTL →
KYTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KYTXCurrent | $0 | - | - | - | |
 AUTL | $10M | +406.7% | +28.3% | -2385.6% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 LEGN | $1.0B | +64.2% | +68.9% | -13.3% |
KYTX Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-2,133,000 | - | $-142,604,000 | - |
| 2023 | $0 | -100.0% | $-1,707,000 | - | $-62,406,000 | - |
| 2022 | $7.0M | +24.2% | $7.0M | 100.0% | $-29,384,000 | -418.3% |
| 2021 | $5.7M | - | $5.7M | 100.0% | $-26,346,000 | -465.8% |
See KYTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KYTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KYTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKYTX — Frequently Asked Questions
Quick answers to the most common questions about buying KYTX stock.
Is KYTX's revenue growth accelerating or slowing?
KYTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is KYTX's long-term revenue growth rate?
Kyverna Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is KYTX's revenue distributed by segment?
KYTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2024 are available for download. Segment mix reveals concentration and diversification trends.